Jennifer Barrett, Associate Editor


FDA Oks 2-Drug HIV Therapy for Previously Untreated Patients

April 08, 2019

To be eligible for dolutegravir and lamivudine, patients must have no history of antiretroviral therapy (ART) and no known or suspected substitutions associated with resistance to the individual components of the regimen.

FDA OKs First Short-Course Oral Therapy for Relapsing Forms of MS

March 31, 2019

THE FDA has approved cladribine (Mavenclad, EMD Serono), a new oral treatment for relapsing forms of multiple sclerosis (MS) in adults including relapsing-remitting disease and active secondary progressive disease.